Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/216344
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | The peptidoglycan and biofilm matrix of Staphylococcus epidermidis undergo structural changes when exposed to human platelets |
Autor: | Loza-Correa, María; Ayala, Juan A.; Perelman, Iris; Hubbard, Keith; Yi, Qi-Long; Taha, Mariam; Pedro, Miguel Ángel de CSIC; Ramirez-Arcos, Sandra | Fecha de publicación: | 25-jun-2019 | Editor: | Public Library of Science | Citación: | PLoS ONE 14 (2019) | Resumen: | Staphylococcus epidermidis is a bacterium frequently isolated from contaminated platelet concentrates (PCs), a blood product used to treat bleeding disorders in transfusion patients. PCs offer an accidental niche for colonization of S. epidermidis by forming biofilms and thus avoiding clearance by immune factors present in this milieu. Using biochemical and microscopy techniques, we investigated the structural changes of the peptidoglycan (PG) and the biofilm matrix of S. epidermidis biofilms formed in whole-blood derived PCs compared to biofilms grown in glucose-supplemented trypticase soy broth (TSBg). Both, the PG and the biofilm matrix are primary mechanisms of defense against environmental stress. Here we show that in PCs, the S. epidermidis biofilm matrix is mainly of a proteinaceous nature with extracellular DNA, in contrast to the predominant polysaccharide nature of the biofilm matrix formed in TSBg cultures. PG profile studies demonstrated that the PG of biofilm cells remodels during PC storage displaying fewer muropeptides variants than those observed in TSBg. The PG muropeptides contain two chemical modifications (amidation and O-acetylation) previously associated with resistance to antimicrobial agents by other staphylococci. Our study highlights two key structural features of S. epidermidis that are remodeled when exposed to human platelets and could be used as targets to reduce septic transfusions events. | Versión del editor: | http://dx.doi.org/10.1371/journal.pone.0211132 | URI: | http://hdl.handle.net/10261/216344 | DOI: | 10.1371/journal.pone.0211132 | Identificadores: | doi: 10.1371/journal.pone.0211132 issn: 1932-6203 |
Aparece en las colecciones: | (CBM) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
AyalaJA_Thepeptidoglycan.pdf | 2,23 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
9
checked on 28-abr-2024
SCOPUSTM
Citations
13
checked on 24-abr-2024
WEB OF SCIENCETM
Citations
10
checked on 29-feb-2024
Page view(s)
103
checked on 28-abr-2024
Download(s)
63
checked on 28-abr-2024